Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Accumulated Expenses: 2017-2025

Historic Other Accumulated Expenses for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $141.0 million.

  • Arcus Biosciences' Other Accumulated Expenses rose 45.36% to $141.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.0 million, marking a year-over-year increase of 45.36%. This contributed to the annual value of $123.0 million for FY2024, which is 61.84% up from last year.
  • Arcus Biosciences' Other Accumulated Expenses amounted to $141.0 million in Q3 2025, which was up 28.18% from $110.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Other Accumulated Expenses registered a high of $141.0 million during Q3 2025, and its lowest value of $23.0 million during Q1 2021.
  • Over the past 3 years, Arcus Biosciences' median Other Accumulated Expenses value was $80.0 million (recorded in 2023), while the average stood at $89.0 million.
  • Per our database at Business Quant, Arcus Biosciences' Other Accumulated Expenses skyrocketed by 238.67% in 2021 and then fell by 1.59% in 2022.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Other Accumulated Expenses stood at $54.0 million in 2021, then spiked by 40.74% to $76.0 million in 2022, then remained steady at $76.0 million in 2023, then skyrocketed by 61.84% to $123.0 million in 2024, then skyrocketed by 45.36% to $141.0 million in 2025.
  • Its Other Accumulated Expenses stands at $141.0 million for Q3 2025, versus $110.0 million for Q2 2025 and $98.0 million for Q1 2025.